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Abstract
 
Psoriasis is a common T cell–mediated autoimmune disorder where primary onset of skin lesions
is followed by chronic relapses. Progress in defining the mechanism for initiation of pathological
events has been hampered by the lack of a relevant experimental model in which psoriasis
develops spontaneously. We present a new animal model in which skin lesions spontaneously
developed when symptomless prepsoriatic human skin was engrafted onto AGR129 mice,
deficient in type I and type II interferon receptors and for the recombination activating gene 2.
Upon engraftment, resident human T cells in prepsoriatic skin underwent local proliferation.
T cell proliferation was crucial for development of a psoriatic phenotype because blocking of
T cells led to inhibition of psoriasis development. Tumor necrosis factor-
 
 
 
 was a key regulator
of local T cell proliferation and subsequent disease development. Our observations highlight
the importance of resident T cells in the context of lesional tumor necrosis factor-
 
 
 
 production
during development of a psoriatic lesion. These findings underline the importance of resident
immune cells in psoriasis and will have implications for new therapeutic strategies for psoriasis
and other T cell–mediated diseases.
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Introduction
 
Psoriasis represents one of the most common T cell–mediated
autoimmune diseases (1–5). The initial onset of skin lesions is
followed by chronic relapses of disease, not unlike the clinical
course for multiple sclerosis or rheumatoid arthritis (6). Based
on various animal models (7–9) and indirect clinical observa-
tions (1, 6), T cells responsible for psoriatic skin lesions are
thought to be confined to the circulating pool of immune
cells. However, the role of resident T cells in the develop-
ment of psoriatic lesions has not been investigated yet, mainly
due to the lack of an appropriate animal model. Current
psoriasis mouse models using SCID mice necessitate the
injection of activated PBMCs with or without superantigen
to induce a psoriatic phenotype in the human prepsoriatic
skin graft (7, 8). SCID (and recombinase activating gene
(RAG)
 
 
 
/
 
 
 
) mice lack T and B cells but show mature NK
cells with normal NK cell activity (10–12). Since NK cells are
involved in rejection of xenogeneic tissue (13), SCID mice
are not ideal acceptors of human skin grafts. To improve graft
acceptance, we used mice deficient in type I (A) and type II
(G) IFN receptors in addition to being RAG-2
 
 
 
/
 
  
 
(AGR129
mice). AGR129 mice show immature NK cells with severely
impaired cytotoxic (cytolytic) activity in vitro and in vivo
(unpublished data) due to a deficiency in type I (A) and type
II (G) IFN receptors, in addition to lacking T and B cells
(RAG-2
 
 
 
/
 
 
 
) (14). Disruption of both IFN receptors has been
previously shown to lead to decreased NK cytotoxic (cy-
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tolytic) activity in vitro and in vivo (15), whereas type I IFN
receptor– or type II IFN receptor–deficient mice demon-
strated reduced but fully functional NK cell activity (12,
16). In the current study, we use AGR129 mice as excellent
acceptors of human prepsoriatic skin grafts to show sponta-
neous onset of bona fide psoriatic lesions that do not require
any exogenous cells or factor except for those contained
within the engrafted skin itself. Our observations establish
proliferation of local T cells, dependent on TNF-
 
 
 
 produc-
tion, as essential elements of psoriatic lesion formation.
 
Materials and Methods
 
Animals, Patients, and Transplantation Procedure.
 
AGR129, mice,
mice deficient in type I (A) and type II (G) IFN receptors in addi-
tion to being RAG-2
 
 
 
/
 
 
 
; AR129 mice, mice deficient in type I
(A) IFN receptors in addition to being RAG-2
 
 
 
/
 
 
 
; and GR129
mice, mice deficient in type II (G) IFN receptors in addition to
being RAG-2
 
 
 
/
 
 
 
 were either on a 129Sv/Ev or C57BL/6 back-
ground. Mice were kept pathogen free throughout the study. An-
imal studies were approved by the Kantonale Veterinaeramt of
Zurich and human studies by the Institutional Review Boards of
the University Hospital of Zurich. Keratome biopsies (6 
 
 
 
 2 
 
 
 
0.04 cm) of symptomless prepsoriatic skin (PN skin) were taken
from the lower back or buttock of patients with confirmed
plaque-type psoriasis after informed consent was obtained. No
topical or systemic medication was administered for at least 4 wk
before the study. Skin grafts were transplanted to the back of mice
using an absorbable tissue seal (Vet-Seal; B. Braun Medical AG).
 
Immunohistochemistry, Confocal Laser Scanning Microscopy
(CLSM) Analysis, and Flow Cytometry Analysis.
 
Acetone-fixed
cryostat sections were stained using standard staining techniques.
Unspecific Fc receptor binding of antibodies was measured with iso-
type-matched controls. Unconjugated antibodies used were mono-
clonals to CD1c (Immunotech), CD1d (51.1.3, provided by Dr. S.P.
Balk, Beth Israel Deaconess Medical Center and Harvard Medical
School, Boston, MA), CD3 (Dako), CD4 (Dako), CD8 (Dako),
CD31 (Dako), CD54 (BD Biosciences), HLA-DR (BD Bio-
sciences), IFN-
 
 
 
 (BD Biosciences), IL-12 (R&D Systems), keratin
16 (Sigma-Aldrich), Ki-67 (Dako), TNF-
 
 
 
 (R&D Systems), poly-
clonals to involucrin (Anawa Trading SA), and conjugated CD3-PE
(BD Biosciences), CD69-FITC (BD Biosciences), CD83-PE (Im-
munotech), and TNF-
 
 
 
–FITC (BD Biosciences). Sensitivity of the
flow cytometry analyses was between 1:1,000 and 1:3,000 human to
mouse PBMCs for the anti–human CD3-PE mAb (Fig. S1 A, avail-
able at http://www.jem.org/cgi/content/full/jem.20031482/DC1).
 
Histologic Assessment and Quantification Experiments.
 
Histo-
logic quantification experiments represent the mean of three random
fields with a 400-fold magnification. The acanthosis and papilloma-
tosis index was defined as published (17). The indicated values of
both indices represent the mean of 10 random areas of each sample.
 
Quantitative Real-time RT-PCR.
 
Total RNA was extracted
from organs (High Pure RNA Isolation kit; Roche) followed by
reverse transcription (AMV First Strand cDNA Synthesis kit;
Roche). Real-time PCR was performed in a LightCycler
(Roche). Primer sequences were for human GAPDH, 5
 
 
 
-AT-
TGCCCTCAACGACCACTTTG-3
 
 
 
 and 5
 
 
 
-TTGATGGTA-
CATGACAAGGTGCGG-3
 
 
 
 and
 
 
 
mouse GAPDH, 5
 
 
 
-CAT-
CAAGAAGGTGGTGAAGC-3
 
 
 
 and 5
 
 
 
-CCTGTTGCTGT-
AGCCGTATT-3
 
 
 
. Sensitivity of the RT-PCR method was
between 1:100,000 and 1:1,000,000 human PBMCs to mouse
splenocytes for the human GAPDH primer (Fig. S1 B), and its
Figure 1. Development of a psoriatic phenotype in symptomless pre-
psoriatic skin after transplantation onto AGR129 mice. Microscopic (A) and
macroscopic (B) appearance of PN skin on the day of transplantation was
comparable to normal human skin. PN skin 6–8 wk after transplantation
onto AGR129 mice developed typical histological features of psoriasis such
as parakeratosis (nucleated keratinocytes in stratum corneum), focal loss of
the granular cell layer, acanthosis (hyperplasia of viable epidermis), papillo-
matosis (elongation of dermal papillae), prominent vessels of the papillary
dermis, and numerous mononuclear cells representing immune cells (C).
Typical clinical signs of psoriasis such as elevation, erythema, induration,
and scaling could be observed (D). Histology of a biopsy of a psoriasis lesion
from the same patient donating the PN skin graft (E). Control grafting
experiments such as PN skin grafts onto GR129 mice (GR) (F) and skin
from healthy individuals (NN skin) onto AGR129 mice (G) 8 wk after
transplantation. The microscopic changes were quantified using papilloma-
tosis and acanthosis indices of PN skin transplants onto AGR129 mice before
transplantation (day 0) and on day 28, 42, and 56 after transplantation (H).
Controls were skin grafts 56 d after transplantation: PN skin transplants
onto RAG-2 /  mice (PN onto RAG), AR129 mice (PN onto AR), and
GR129 mice (PN onto GR), and NN skin from three healthy individuals
onto AGR129 mice (NN onto AGR) (H). Dashed lines indicate border
between epidermis above and dermis below. n, number of grafted mice.
Error bars represent one SD. Bars: (A, C, and E–G) 100  m; (B and D)
2 mm. n.s., not significant. *, P   0.0002; **, P   0.005, unpaired t test.
 
specificity for human cDNA was demonstrated by the lack of am-
plification of specific cDNA sequences when applied on RNA
isolated from spleens of normal C57BL/6 mice. 
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Neutralization Studies.
 
Dosage and route of administration of
the reagents applied was deduced from therapeutic trials in hu-
mans, calculated using the allometric approach, and administered
as follows: 17 
 
 
 
g muromonab-CD3 (neutralizing anti–human
CD3 mAb, clone OKT3) twice weekly, i.v.; 1,000 
 
 
 
g infliximab
(anti–human TNF-
 
 
 
 mAb) on days 0, 14, 28, 42, and 56, i.v.; 90
 
 
 
g etanercept (TNF receptor fusion protein) twice weekly, s.c.
Control mice received isotype-matched antibodies or PBS.
 
Online Supplemental Material. 
 
Fig. S1 shows the detection
threshold for flow cytometry and RT-PCR analyses, and Fig. S2
shows TNF-
 
 
 
 production by few T cells. Figs. S1 and S2 are avail-
able at http://www.jem.org/cgi/content/full/jem.20031482/DC1.
 
Results and Discussion
 
Spontaneous Development of a Psoriatic Phenotype upon
Transplantation of Symptomless Prepsoriatic Skin onto AGR129
Mice. 
 
PN skin from 12 different patients with confirmed
plaque-type psoriasis was transplanted onto AGR129 mice.
The skin grafts developed a psoriatic phenotype in 28 out
of 31 (90%) grafted mice. Phenotypic conversion started at
week 4 and was fully developed at 6–8 wk after engraft-
ment. Appearance of PN skin on the day of transplantation
(Fig. 1, A and B) was comparable to normal human skin. In
contrast, 8 wk after transplantation onto AGR129 mice,
PN skin grafts showed typical features of psoriasis (Fig. 1, C
and D). Histology of PN skin after development of a psori-
atic phenotype (Fig. 1 C) was comparable to a biopsy of a
psoriasis lesion from the same patient donating the PN skin
graft (Fig. 1 E). Several different combinations of human
skin and mouse strains served to demonstrate that develop-
ment of a psoriatic phenotype was unique to PN skin trans-
planted onto AGR129 mice (Fig. 1, F–H). Quantification
of psoriatic features in a time-course experiment using pap-
illomatosis and acanthosis indices (17) reflected significant
(P
 
 
 
  
 
0.0002) changes of PN skin transplants on AGR129
mice, whereas changes in phenotype were clearly absent
from control skin grafts (Fig. 1 H).
To further confirm that the morphologic changes of PN
skin transplanted onto AGR129 mice were consistent with
psoriasis, immunohistochemical analyses of PN skin before
transplantation (Fig. 2, pre) and 6–8 wk after transplana-
tion (Fig. 2, post) was performed. In summary, upon
transplantation of PN skin onto AGR129 mice, resident
skin cells including epidermal keratinocytes, DCs, endo-
thelial cells, and immune cells became activated to create
fully fledged psoriasis.
 
Resident T Cells Are Essential for Development of Lesions.
 
Currently existing psoriasis models implicate the importance
of circulating T cells being recruited to the site of lesion (7,
8). However, they do not address the role of resident T cells
during development of lesions, mainly due to the lack of an
appropriate model system. The present psoriasis model al-
lowed us to address this issue. Immunohistochemical analy-
ses of PN skin before transplantation (Fig. 3, A and B, pre),
compared with 6–8 wk after transplantation onto AGR129
mice (Fig. 3, A and B, post), revealed a more than twofold
increase in total T cell numbers (P
 
 
 
  
 
0.002), which corre-
sponds to an almost fivefold increase in the tissue. We dem-
onstrated a preference of CD4-positive cells for the dermis,
whereas CD8-positive cells were located predominantly in
the epidermis or the dermo-epidermal junction zone (Fig. 3
A). This finding corresponds to observations in human pso-
riasis samples (18). Proliferation of lesional CD3-positive
cells paralleled disease formation (Fig. 3 B). T cell prolifera-
tion predominantly took place in the dermis, peaked at 4
wk after transplantation, and was followed by a decrease in
the dermis and a simultaneous increase of T cells in the epi-
dermis (Fig. 3 B). These data suggest a migration of human
dermal T cells into the epidermis during psoriasis formation.
Increase in the number of lesional T cells could be due to
local proliferation or recruitment of T cells recirculating and
proliferating extracutaneously in the immunodeficient mice
(19). To test the second possibility, we investigated PBMCs,
LNs, and spleens of PN skin–transplanted AGR129 mice 8
wk after engraftment for the presence of human T cells. No
T cells could be detected in LNs, spleen, or PBMCs neither
Figure 2. Epidermal hyperproliferation, blood vessel formation, and
immune activation. In contrast to the appearance of PN skin before trans-
plantation (pre), 6–8 wk after transplantation onto AGR129 mice (post)
keratin 16 was expressed throughout the epidermis and involucrin-positive
cell layers were increased, indicating aberrant epidermal differentiation.
Whereas before no marked expression of intercellular adhesion molecule-1
(ICAM-1) and MHC class II by keratinocytes could by observed, trans-
plantation onto AGR129 mice and development of a psoriatic phenotype
led to up-regulation of these markers, indicating activation of kerati-
nocytes (ICAM-1, arrowhead). Strong suprabasal expression of Ki-67
demonstrated a hyperproliferative epidermal compartment in addition to
proliferating dermal cells. Marked new blood vessel formation was shown
by platelet endothelial cell adhesion molecule-1 (PECAM-1) staining. An
activated immune compartment was observed including expanded CD1d-
positive APCs in the epidermis (arrows) and dermis as well as proinflam-
matory cytokines such as TNF- , IL-12, and IFN- . Dashed lines indicate
border between epidermis above and dermis below. Bars, 50  m. 
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by immunohistochemistry, flow cytometry, nor RT-PCR
analyses (Fig. 3, C–E). The local increase in T cells could
reflect a nonrelevant proliferation or indicate a crucial con-
tribution of activated T cells to disease development. T cells
expressed the activation marker CD69 during psoriasis de-
velopment (unpublished data). We blocked T cell func-
tion  using the monoclonal anti–human CD3 antibody
muromonab-CD3 (OKT3) over 8 wk starting after trans-
plantation of PN skin onto AGR129 mice. Injection of
muromonab-CD3 inhibited development of a psoriatic
phenotype (Fig. 3 F) and compared with mice receiving
isotype-matched control antibody induced a significant
(P
 
 
 
  
 
0.0001) reduction of the papillomatosis and acanthosis
index in 12 out of 12 mice grafted with PN skin from three
different patients (Fig. 3 G). We further showed the impor-
tance of proliferating T cells during development of lesions
by administration of a neutralizing anti–human IL-2 mAb
(unpublished data). These experiments clearly show the es-
sential role of locally activated and proliferating resident T
cells during psoriasis development in our model system. We
cannot rule out an involvement of recruited T cells in psori-
atic lesion formation in general. However, due to the high
sensitivity of the methods employed (Fig. S1) recirculation
and recruitment of human T cells cannot play a major role
in our model. In support of our findings, there is evidence
from other models of autoimmune-type inflammatory dis-
eases that local proliferation of effector T cells, rather than
their recruitment, are important for disease induction (20).
 
TNF-
 
 
 
 Is Crucial for Local T Cell Proliferation and Psoriasis
Development. 
 
The concept of an altered cytokine net-
work is central to the pathogenesis of psoriasis and other
autoimmune-type inflammatory diseases (21, 22). In recent
clinical trials, the usage of a mAb against TNF-
 
 
 
 (inflix-
imab) or a soluble TNF receptor fusion protein (etaner-
cept) resulted in disease improvement in psoriasis patients,
suggesting a role for TNF-
 
 
 
 in the pathogenesis of psoriasis
(23, 24). Although supporting the importance of TNF-
 
 
 
 in
maintaining established psoriatic lesions, these studies did
not investigate the role of TNF-
 
 
 
 during lesion develop-
ment. In our model, TNF-
 
 
 
 was predominantly localized
to APCs (Fig. 4, A and B). TNF-
 
 
 
 was also observed in
few dermal T cells (Fig. S2, available at http://www.
jem.org/cgi/content/full/jem.20031482/DC1) but not
keratinocytes or fibroblasts. Injection of a neutralizing anti–
human TNF-
 
 
 
 mAb or a TNF receptor fusion protein
over 8 wk inhibited the development of psoriatic pheno-
type in eight out of nine mice grafted with PN skin from
three different patients (Fig. 4, C and D). PN skin grafts in
Figure 3. Resident T cells during development
of lesions. CD3, CD4, and CD8 immunostaining
of PN skin before transplantation (pre) compared
with 6–8 wk after transplantation onto AGR129
mice (post) (A). Epidermal (B, dotted line), dermal
(B, dashed line), and total (B, thick solid line) CD3
counts in PN skin grafts before transplantation (day
0) and on day 28, 42, and 56 after transplantation
onto AGR129 mice. The thin solid line indicates
acanthosis index. CD3 immunostaining of LN (C),
spleen (D), and flow cytometry of PBMCs (D, insert;
isotype control, gray area; CD3 staining, red line)
from AGR129 mice 56 d after transplantation of
PN skin grafts. RT-PCR analyses of cDNA from
human PBMCs (hPBMC), mouse PBMCs
(mPBMC), mouse spleen (mSpleen), and mouse
LNs (mLN) from AGR129 mice 56 d after trans-
plantation of PN skin using primers for human
GAPDH (hGAPDH) and mouse GAPDH
(mGAPDH) (E). Spleen of untreated C57BL/6
mice (BL/6 Spleen) served as control to show spec-
ificity of the primers used. Hematoxylin staining of
PN skin grafted onto AGR129 mouse and blocking
of T cells with an anti–human CD3 mAb for 8 wk
(F). Papillomatosis and acanthosis indices of PN
skin transplants onto AGR129 mice before trans-
plantation (day 0), 56 d after transplantation and
administration of isotype-matched antibody (iso-
type control) or of an anti–human CD3 mAb (anti-
CD3) (G). Dashed lines, n, and error bars are defined
as in the legend to Fig. 1. Bars, 70  m. *, P   0.01;
**, P   0.0001, unpaired t test. 
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mice receiving anti–TNF-
 
 
 
 treatment showed markedly
reduced TNF-
 
 
 
 levels in contrast to PN skin converted to
a psoriatic phenotype (Fig. 4, E and F). Papillomatosis and
acanthosis indices were significantly decreased (P
 
 
 
  
 
0.01)
in mice treated with an anti–TNF-
 
 
 
 treatment (Fig. 4 G).
Neutralization of TNF-
 
 
 
 was accompanied by a significant
decrease (P
 
 
 
  
 
0.004) of T cells in the graft (Fig. 4 H), sug-
gesting a feedback loop between T cell proliferation and
TNF-
 
 
 
 production as described for monocytes and sug-
gested for T cells (25). These data demonstrate that devel-
opment of psoriatic lesions is mediated by TNF-
 
 
 
 and in-
dicate that proliferation of resident T cells is dependent on
local TNF-
 
 
 
 production.
In conclusion, our findings, based on a novel autoim-
mune mouse model, strongly support the view that activa-
tion of resident T cells is necessary and sufficient for devel-
opment of lesions in psoriasis. Local T cells are key players
in this process, depending on a cytokine network governed
by the primary cytokine TNF-
 
 
 
. These findings could
have relevance for other common autoimmune diseases
such as multiple sclerosis and rheumatoid arthritis, and new
pharmacological agents could be envisioned focusing on
resident immune cells.
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